Despite initial interest in targeting FAP for cancer treatment, a phase II exploratory trial of monoclonal antibody sibrotuzumab targeting FAP in metastatic colorectal cancer was discontinued early as it did not show efficacy (58). This evidence concerns the gene FAP and metastatic colorectal cancer.